Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,
Go back to Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 152.72 +1.90 (1.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.82 | 52 Week High | $58.46 | |||
| Open | $149.72 | 52 Week Low | $31.25 | |||
| Day High | $153.42 | P/E | N/A | |||
| Day Low | $148.78 | EPS | $-0.69 | |||
| Volume | 1,305,148 | |||||
